AbbVie Inc (ABBV)

ABBV (NYSE:Drugs)
$62.26
neg -0.84
-1.30%
Today's Range: 61.69 - 63.56 | ABBV Avg Daily Volume: 7,138,000
Last Update: 01/29/15 - 9:13 AM EST
Volume: 6,910,126
YTD Performance: -5.49%
Open: $63.43
Previous Close: $63.10
52 Week Range: $45.50 - $70.76
Oustanding Shares: 1,593,265,381
Market Cap: 100,535,045,541
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 8 6 6
Moderate Buy 0 0 1 1
Hold 4 3 3 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.73 1.55 1.65 1.50
Latest Dividend: 0.49
Latest Dividend Yield: 3.11%
Dividend Ex-Date: 01/13/15
Price Earnings Ratio: 27.43
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
27.43 27.40 25.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.51% 29.69% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.20 0.00 0.00
Net Income -21.70 0.00 0.00
EPS -23.10 0.00 0.00
Earnings for ABBV:
EBITDA 6.56B
Revenue 18.79B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.85 $0.85 $3.29 $4.51
Number of Analysts 6 3 10 8
High Estimate $0.90 $0.89 $3.32 $5.00
Low Estimate $0.82 $0.77 $3.25 $4.30
Prior Year $0.82 $0.72 $3.14 $3.29
Growth Rate (Year over Year) 4.07% 17.59% 4.68% 37.13%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Update
Jan 14, 2015 | 6:41 AM EST
JPMorgan Healthcare Conference (Day 3 of 4) - 01/12/15 - 01/15/15 San Francisco, CA
Bearish
Jan 09, 2015 | 7:09 AM EST
ABBV was downgraded to Neutral, Bank of America/Merrill Lynch said. Valuation call, based on a $70 price target. 

Why I'm Sticking With Biotech Real Money Pro($)

They offer a nice shelter for the headwinds now hitting equities.
Its hepatitis C drug will dominate the market.

Gilead Is a Buying Opportunity Real Money Pro($)

Its hepatitis C drug is better; the stock trades at a discount.
Stocks that do well when the economy rises are shining.

In Defense of Gilead Sciences Real Money Pro($)

It has a great long-term future.
It might be good for consumers, but not for the stock.

Three Large-Cap Growth Stocks Real Money Pro($)

I would pick up some large caps on any significant dips.
Bearish
Dec 11, 2014 | 7:20 AM EST
ABBV was downgraded from Overweight to Equal-weight, Morgan Stanley said. $72 price target. Stock is already pricing in potential for H...

Columnist Conversations

FIBOCALL: The S&P futures closed below the 100 Daily Moving Average on 12/16/14 and then bounced over 6% ...
It wasn't long ago when the dollar was being cracked and the worry was the Fed was doing the work with their Q...
Had the chance to chat with the CEO of Tupperware for TheStreet. Be on the lookout for news at a key NYC analy...
POT
Potash is trading to a new high in premarket trading after a eight percent hike in the dividend late yesterday...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.